Finding kinder drugs in genetically matched cell models for childhood leukaemia
Professor Alex Thompson and his team at the University of Nottingham aim to learn more about leukaemia to support the development of kinder treatments.
Creating advanced models to test new treatments for malignant rhabdoid tumours
Dr Daniel Williamson’s expert team will find the best malignant rhabdoid tumour models to test exciting new treatments.
Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Making CAR-T cells that can rest to improve their cancer-fighting ability
Professor John Anderson’s team at University College London Great Ormond Street Institute of Child Health aim to revolutionise CAR T-cell therapy for solid tumours.
Finding the best way to make two cancer-targeting T cells for the price of one
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.
Unravelling the behaviour of individual lymphoma cells to find out why the cancer can relapse or resist treatment
Professor Suzanne Turner will investigate the behaviour of individual lymphoma cells in order to find out why treatments fail.
Investigating the role of SET in childhood acute myeloid leukaemia to develop new treatments
Dr Maria Teresa Esposito hopes to learn more about a gene called SET in leukaemia and will test the best medicines to fight it.
Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Finding the most beneficial dose of fludarabine to optimise CAR-T therapy
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.